Incyte Corp. INCY shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK blood-cancer treatment, Ojjaara, that will compete with Incyte’s Jakafi. The FDA approved Ojjaara for use in patients with myelofibrosis, a rare blood cancer, with anemia. Ojjaara will likely put pressure on uptake of Jakafi as a first-line treatment for myelofibrosis, Truist Securities analysts wrote in a note Friday. The analysts maintained their buy rating on Incyte shares, saying they don’t anticipate that Ojjaara will impact Jakafi revenues from two other conditions, polycythemia vera and graft-versus-host disease. Incyte shares have dropped more than 22% in the year to date, while the S&P 500 has gained 15.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Read Full Story
- Earnings Results: Olive Garden parent Darden’s earnings buoyed by addition of 77 Ruth’s Chris Steak Houses locations - September 21, 2023
- Mark Hulbert: The U.S. could be in a recession and we just don’t know it yet - September 21, 2023
- : Starbucks’ new dividend boosts yield to 2.4% - September 21, 2023
